Pakdaman H, Fallah A, Sahraian M A, Pakdaman R, Meysamie A
Neurology, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran.
Neuropediatrics. 2006 Aug;37(4):257-60. doi: 10.1055/s-2006-924723.
Patients with early onset multiple sclerosis may develop disability at a younger age than adults. There are several reports about safety of beta interferons in childhood and juvenile MS with different doses.
To determine safety and efficacy of substandard dose of intramuscular interferon beta-1a in a prospective randomized trial in patients with multiple sclerosis under the age of 16.
Sixteen patients were divided into two groups randomly. The first group was treated with intramuscular interferon beta-1a 15 micrograms once a week and the second group received no disease-modifying therapy.
The patients were followed for four years. There was no significant side effect and none of the treated patients discontinued the drug. There were significant differences between two groups regarding relapse rates (p = 0.04), disability progression (p = 0.01), and new T2 lesions (p = 0.006).
Treatment with interferon beta-1a is well tolerated for a long period of time and may be effective in substandard doses in early onset multiple sclerosis.
早发型多发性硬化症患者可能比成年人在更年轻的时候出现残疾。有几篇关于不同剂量β干扰素在儿童和青少年多发性硬化症中的安全性报告。
在一项前瞻性随机试验中，确定低于标准剂量的肌肉注射β-1a干扰素对16岁以下多发性硬化症患者的安全性和疗效。
16名患者被随机分为两组。第一组接受每周一次15微克肌肉注射β-1a干扰素治疗，第二组未接受疾病改善治疗。
患者随访四年。没有明显副作用，且接受治疗的患者均未停药。两组在复发率（p = 0.04）、残疾进展（p = 0.01）和新的T2病灶（p = 0.006）方面存在显著差异。
β-1a干扰素治疗长期耐受性良好，且在早发型多发性硬化症中低于标准剂量可能有效。
Zotero 插件